Eli Lilly and Co
1LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,928.70 | 1.20 | -0.01% |
| CAC 40 | 8,124.88 | 56.26 | 0.70% |
| DAX 40 | 24,229.91 | 43.42 | 0.18% |
| Dow JONES (US) | 48,416.56 | 41.49 | -0.09% |
| FTSE 100 | 9,751.31 | 102.28 | 1.06% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,057.41 | 137.76 | -0.59% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,430.29 | 22.15 | 0.17% |
| S&P 500 | 6,816.51 | 10.90 | -0.16% |
| S&P/ASX 200 | 8,642.50 | 4.80 | -0.06% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |